C4 Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CCCC and other ETFs, options, and stocks.About CCCC
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system.
CEOAndrew J. Hirsch
CEOAndrew J. Hirsch
Employees110
Employees110
HeadquartersWatertown, Massachusetts
HeadquartersWatertown, Massachusetts
Founded2015
Founded2015
Employees110
Employees110
CCCC Key Statistics
Market cap241.83M
Market cap241.83M
Price-Earnings ratio-1.47
Price-Earnings ratio-1.47
Dividend yield—
Dividend yield—
Average volume1.62M
Average volume1.62M
High today$2.50
High today$2.50
Low today$2.42
Low today$2.42
Open price$2.47
Open price$2.47
Volume707.86K
Volume707.86K
52 Week high$5.10
52 Week high$5.10
52 Week low$1.09
52 Week low$1.09
Stock Snapshot
As of today, C4 Therapeutics(CCCC) shares are valued at $2.48. The company's market cap stands at 241.83M, with a P/E ratio of -1.47.
As of 2025-11-25, C4 Therapeutics(CCCC) stock has fluctuated between $2.42 and $2.50. The current price stands at $2.48, placing the stock +2.5% above today's low and -0.6% off the high.
The C4 Therapeutics(CCCC)'s current trading volume is 707.86K, compared to an average daily volume of 1.62M.
During the past year, C4 Therapeutics(CCCC) stock moved between $1.09 at its lowest and $5.10 at its peak.
During the past year, C4 Therapeutics(CCCC) stock moved between $1.09 at its lowest and $5.10 at its peak.
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CCCC. This list is generated using Robinhood data, and it’s not a recommendation.